Streetwise Reports: The Gold Report, The Energy Report, The Life Sciences Report and Streetwise Reports
755 Baywood Dr, Second Floor
Petaluma, CA 94954
(707) 981-8999 ext: 327
Streetwise Reports: The Gold Report, The Energy Report, The Life Sciences Report and Streetwise Reports are free publications of Streetwise Reports. If you would like to subscribe, please complete our online form.
Interested in becoming a sponsor or an Advertiser?
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
|"INO continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges."|
|"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."|
|"RVX remains gravely undervalued at the current share price."|
|"We initiate with an Outperform on VIVE."|
|"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."|
|"We continue to be optimistic about DRRX's story."|
|"We continue to be buyers of VIVE following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance."|
|"RXII developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds."|
|"We see the main value-creating events as initiation of INO's Phase III in cervical dysplasia and data in HIV and Zika later this year."|